Viking Therapeutics IncNASDAQ VKTX Stock Report

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2015-04-29. The firm's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRb). The firm is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The company is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The company is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. The Company’s other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).